AqVida steps up presence at CPhI Madrid
Press Release | AqVida GmbH
SEPTEMBER 02, 2015
Hamburg, Germany: – Innovative German oncology generics specialist AqVida will double its presence at Europe’s CPhI Worldwide expo for 2015.
The Hamburg-based company, which is dedicated to development, registration, manufacturing and licensing/distribution of oncology generics, will be an exhibitor at CPHI 2015 in Madrid, with an AqVida stand (Booth 10H2, Hall 10) twice the size that it occupied at last year’s Paris show.
AqVida will use CPhI 2015 to introduce its New Generic products such as Imatinib and Sunitinib, targeting patent expiries in 2016 and 2021 respectively, as well pipeline developments.
It will also showcase its new “Zero Loss” facility to manufacture oncology generics and antibody drug conjugates (ADCs). This facility is a major innovation for the pharma industry, using a totally robotic controlled filling processes in an isolator for parenteral cytotoxics.
AqVida CEO and founder Wolfgang Heinze was inspired by the impact of JIT techniques on the supply chain of the automotive industry in which spare parts are available at only a few hours lead-time. This compares with equivalent lead-times of several months in the healthcare sector for product schedule, manufacturing, batch release and supply.
“Shorter lead-times are also key to maintaining AqVida’s ‘Quality is Core’ principle, in which it is extremely important and beneficial to maintain and provide a maximum of flexibility to our partner,” commented. Mr. Heinze.
“A further advantage of introducing such technology is that it maximizes the product safety and quality and thus, the ‘Made in Germany’ factor that is one of AqVida’s main brand strengths,” added Mr. Heinze, who will be present at CPhI Madrid.
AqVida is a regular attender at CPhI Worldwide, which is a centerpiece “must attend” event for pharmaceutical companies from all over the world. CPhI 2015 is expected to attract visitors and exhibitors from some 150 countries.
“We enjoyed a very successful presence at CPhI in Paris last year and are expecting 2015 to be even better,” said AqVida’s Commercial Director, Jürgen Lehmberg.
“This year, we are expecting to meet even more partners from Europe, Latin America, Middle East and North Africa, South East Asia and Sub-Saharan African area for networking, finalizing negotiations and to build up long-term business relationships,” said Mr. Lehmberg.
“We will use CPhI to connect with licensing and distribution partners across Europe to expand our presence there and in other regulated markets, such as South Africa, Canada and Australia,” Mr. Lehmberg explained.
AqVida will also look to open negotiation with new license partners on co-development projects to realize synergies, bundling strengths and combined development forces for greater efficiencies and mutual benefit.
“We have several opportunities available for out-licensing of our products, depending on client portfolio and market stance,” Wolfgang Heinze noted.
He said AqVida was particularly keen to talk to pharmaceutical companies looking to bring “Made in German”-quality of GMP certified oncology products to their markets. The company was actively seeking professional partners with identical company philosophy to register and distribute AqVida’s product family into its home markets.
“A growing number of pharmaceutical companies especially in Asia, Africa and South America are looking for alternatives in generic oncologic supply as quality requirements become ever more stringent, in Europe and beyond. AqVida is able to match these needs with EU quality products at a competitive price level and several other benefits, such as keeping inventory, short lead-time, dossier maintenance, etc. AqVida is a full service pharmaceutical company that is also very fast and flexible in finding optimum solutions for our clients,” said Mr. Heinze.
AqVida is a German pharmaceutical company that is fully dedicated and specialized in the development, registration, manufacturing and distribution of finished dosage forms mainly for the oncology sector. It has developed a portfolio of medicines for treating the most common types of cancer.
AqVida’s expertise in generic oncology products has made the company a leading partner in the pharmaceutical industry.
AqVida works alongside some of the leading names in the oncology sector. In co-operation with its partners, AqVida has achieved substantial development and growth with its oncology portfolio.
As a pharmaceutical company with an impressive track-record, AqVida fulfills all client requirements from API sourcing through to EU market release for finished products. Teams of experts in development, regulatory affairs, patent issues and laboratory work bring skills and knowledge together to achieve optimum results for customers.
AqVida complies with all German and EU legal requirements for the pharmaceutical industry and is GMP certified by the German Health Authorities. As a European organisation, AqVida has the knowledge and resources to provide regulatory support to meet the requirements of the complex and highly regulated EU market.
About CPhI 2015
CPhI Worldwide is the flagship annual trade show for pharma ingredients and partner sourcing providing delegates and exhibitors opportunities to arrange face-to-face meetings with potential international pharmaceutical partners and collaborators, as well as gain insights on latest industry trends.
Now in its 26th year, the 2015 event is a three-day event opening October 13 at IFEMA, Feria de Madrid, Spain. Last year’s even in Paris attracted almost 36,500 delegates and 2,500 exhibitor companies from more than 150 countries worldwide.
The CPhI series is staged by leading Global B2B Events Organizer and Publisher UBM Live More information at: http://www.cphi.com/europe/home
Jürgen Lehmberg, Commercial Director, AqVida GmbH
Tel: +49 40 380 37190